
William Montfort
· MathematicsVerifiedUniversity of Arizona · Physics
Active 1984–2024
Research topics
- Biology
- Chemistry
- Cell biology
- Biochemistry
- Genetics
- Cancer research
Selected publications
Extracellular signals induce dynamic ER remodeling through αTAT1-dependent microtubule acetylation
Neoplasia · 2024 · 4 citations
- Cell biology
- Chemistry
- Biology
Dynamic changes in the endoplasmic reticulum (ER) morphology are central to maintaining cellular homeostasis. Microtubules (MT) facilitate the continuous remodeling of the ER network into sheets and tubules by coordinating with many ER-shaping protein complexes, although how this process is controlled by extracellular signals remains unknown. Here we report that TAK1, a kinase responsive to various growth factors and cytokines including TGF-β and TNF-α, triggers ER tubulation by activating αTAT1, an MT-acetylating enzyme that enhances ER-sliding. We show that this TAK1/αTAT1-dependent ER remodeling promotes cell survival by actively downregulating BOK, an ER membrane-associated proapoptotic effector. While BOK is normally protected from degradation when complexed with IP3R, it is rapidly degraded upon their dissociation during the ER sheets-to-tubules conversion. These findings demonstrate a distinct mechanism of ligand-induced ER remodeling and suggest that the TAK1/αTAT1 pathway may be a key target in ER stress and dysfunction.
Sorting nexin-dependent therapeutic targeting of oncogenic epidermal growth factor receptor
Cancer Gene Therapy · 2022 · 18 citations
- Cancer research
- Biology
- Genetics
of ~4.0 µM. In vitro analysis found that cSNX1.3 inhibits the nuclear localization of EGFR. To determine specificity, we evaluated cancer cell lines expressing wildtype EGFR (MDA-MB-468, BT20 and A549), mutant EGFR (H1975) and non-transformed lines (CHO and MCF10A). Only transformed lines expressing wildtype EGFR responded to cSNX1.3, while mutant EGFR and normal cells responded better to an EGFR kinase inhibitor. Phenotypically, cSNX1.3 inhibits EGF-, NRG-, and HGF-dependent migration, but not HA-dependent migration. Together, these data indicate that targeting retrotranslocation of EGFR may be a potent therapeutic for RTK-active cancer.
Recent grants
NIH · $841k · 2004
NIH · $1.1M · 2011
Chemistry-Biology Interface Training Program
NIH · $3.9M · 2003–2024
Nitric Oxide Signaling with Heme Proteins
NIH · $3.4M · 2000–2013
Nitric Oxide Signaling in Health and Disease
NIH · $1.4M · 2015–2020
Frequent coauthors
- 108 shared
A. Weichsel
University of Arizona
- 102 shared
Cheng‐Yu Chen
Biodiversity Research Center, Academia Sinica
- 96 shared
Tarjani Thaker
University of Arizona
- 96 shared
Thomas Tomasiak
University of Arizona
- 95 shared
Cinthia Millán
University of Arizona
- 95 shared
Sarah Young
Erasmus University Rotterdam
- 95 shared
Irina Novikova
Pacific Northwest National Laboratory
- 95 shared
Nancy Meyer
Oregon Health & Science University
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with William Montfort
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup